Carregant...
Tipus de document
Treball de fi de màsterData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227060
Does Earnings Management Drive ESG? An Empirical Study in the European Pharma Sector
Títol de la revista
Autors
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Purpose This study examines whether corporate earnings management is associated with ESG performance levels and whether this relationship underwent structural changes during COVID-19. Using a balanced panel of 50 European pharmaceutical companies from 2019-2023, constructed from Refinitiv and Orbis databases, we examine earnings management's impact on ESG performance across environmental, social, and governance dimensions. We employ fixed-effects regression models with COVID-19 time dummies to capture strategic disclosure behavior changes under macroeconomic shocks.
Findings Results show earnings management does not significantly affect overall ESG scores or individual dimensions, with no significant moderating effects pre- and post-pandemic. However, governance scores exhibit consistent negative correlation with earnings management, suggesting this dimension may better reflect financial motivations underlying actual governance structures.
Originality This study's originality lies in its focus on European pharmaceuticals, its special "EM-drives-ESG" analytical approach, and its novel insights into non-financial disclosure motivations during pandemic conditions.
Descripció
Treballs Finals del Màster de Recerca en Empresa, Facultat d'Economia i Empresa, Universitat de Barcelona. Curs: 2024-2025, Tutor: Antonio Somoza
Matèries (anglès)
Citació
Col·leccions
Citació
CAI, Yunqiong. Does Earnings Management Drive ESG? An Empirical Study in the European Pharma Sector. [consulta: 27 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/227060]